申请人:American Cyanamid Company
公开号:US04680293A1
公开(公告)日:1987-07-14
Novel 3-heteroarylalkyl-1,2,3-benzotriazin-4(3H)-ones, having the structural formula: ##STR1## wherein A is a divalent moiety of the formula: ##STR2## wherein n is an integer from 3 to 10, inclusive; R.sub.1 and R.sub.2 may be the same or different and may be selected from the group consisting of hydrogen, halogen, trifluoromethyl, alkoxy having from one to four carbon atoms, alkyl having from one to four carbon atoms, nitro and amino; wherein Heteroaryl is ##STR3## wherein R.sub.3 and R.sub.4 may be hydrogen, alkyl having from one to four carbon atoms or phenyl and X is CH or N; together with the pharmaceutically acceptable salts thereof; processes for their preparation and their use in treating prostaglandin-related vascular disorders including ischemic heart disease, transient ischemic attack, thrombosis, migraine and hypertension.
3-杂环芳基烷基-1,2,3-苯并三唑啉-4(3H)-酮的结构式为:##STR1##其中A是结构式的二价基团:##STR2##其中n是3到10的整数;R.sub.1和R.sub.2可以相同也可以不同,可以选择自氢、卤素、三氟甲基、含有一至四个碳原子的烷氧基、含有一至四个碳原子的烷基、硝基和氨基的基团;其中Heteroaryl是##STR3##其中R.sub.3和R.sub.4可以是氢、含有一至四个碳原子的烷基或苯基,X是CH或N;以及其药用盐;其制备方法及其在治疗前列腺素相关的血管疾病中的用途,包括缺血性心脏病、短暂性缺血性发作、血栓形成、偏头痛和高血压。